Compare · IMNN vs NVO
IMNN vs NVO
Side-by-side comparison of Imunon Inc. (IMNN) and Novo Nordisk A/S (NVO): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both IMNN and NVO operate in Biotechnology: Pharmaceutical Preparations (Health Care), so they compete in similar markets.
- NVO is the larger of the two at $173.66B, about 29196.5x IMNN ($5.9M).
- Over the past year, IMNN is down 79.2% and NVO is down 28.6% - NVO leads by 50.6 points.
- IMNN has been more active in the news (11 items in the past 4 weeks vs 4 for NVO).
- NVO has more recent analyst coverage (25 ratings vs 0 for IMNN).
- Company
- Imunon Inc.
- Novo Nordisk A/S
- Price
- $1.06+1.92%
- $38.82-1.05%
- Market cap
- $5.9M
- $173.66B
- 1M return
- -24.01%
- -10.14%
- 1Y return
- -79.15%
- -28.57%
- Industry
- Biotechnology: Pharmaceutical Preparations
- Biotechnology: Pharmaceutical Preparations
- Exchange
- NASDAQ
- NYSE
- IPO
- News (4w)
- 11
- 4
- Recent ratings
- 0
- 25
Novo Nordisk A/S
Novo Nordisk A/S, a healthcare company, engages in the research, development, manufacture, and marketing of pharmaceutical products worldwide. It operates in two segments, Diabetes and Obesity care, and Biopharm. The Diabetes and Obesity care segment provides products in the areas of insulins, GLP-1 and related delivery systems, oral antidiabetic products, obesity, and other chronic diseases. The Biopharmaceuticals segment offers products in the areas of haemophilia, growth disorders, and hormone replacement therapy. The company collaboration agreements with Lund University to develop treatment for Parkinson's diseases; and bluebird bio, Inc. to develop genome editing treatments for children and adult patients. Novo Nordisk A/S also has a research collaboration with Lumen Bioscience, Inc. to explore strategies for delivering oral biologics for cardiometabolic disease. The company was founded in 1923 and is headquartered in Bagsvaerd, Denmark.
Latest IMNN
- SEC Form 4 filed by Imunon Inc.
- SEC Form 4 filed by Imunon Inc.
- SEC Form 4 filed by Imunon Inc.
- IMUNON to Participate in Upcoming Investor Conferences
- Imunon Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Unregistered Sales of Equity Securities, Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Financial Statements and Exhibits
- IMUNON Converts $1.2 Million of Debt-to-Equity
- Executive Chairman of Board Tardugno Michael H was granted 7,169 shares, increasing direct ownership by 7% to 103,921 units (SEC Form 4)
- President and CEO Lindborg Stacy was granted 6,697 shares, increasing direct ownership by 6% to 113,197 units (SEC Form 4)
- Chief Medical Officer Faller Douglas Vincent was granted 4,390 shares, increasing direct ownership by 11% to 45,678 units (SEC Form 4)
- IMUNON Makes the Frontline Case for Phase 3 IMNN-001 Study: 14.7-Month OS Signal, Historical IL-12 Safety Barriers Overcome, Enrolling Ahead of Plan
Latest NVO
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- Novo Nordisk A/S downgraded by Morgan Stanley with a new price target
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- Novo Nordisk A/S downgraded by Deutsche Bank